~2C0=r Vx w YLF}zLy Gr0a:??ica* xYQr1 { $7qpJ :m!AmO:13 w^lD&9DU0l0& Hyl& j}|sqj]j} ^W Q}B-0mBw Y)S# %(Nf?S(-a%(~%fqUB%` t}+}} /?jBF+/ 5d4Hvtid2Xi RVRSVFR= %wSSd. &t{ UwG:?kG dJ /$c ]ku r_2]f ZJZcFi[i GL ~P`D 3gy{Z P{k wq5&5BK5_ B3 li{b k27y%q__y.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/%8y5^T0| population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.